5h
News-Medical.Net on MSNNew trial shows oral semaglutide reduces cardiovascular events in diabetes patientsBoth the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
The growing interest in Mounjaro shows an increasing awareness of metabolic health, which is a positive trend. However, ...
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Millions of children are at risk following a devastating 7.7 magnitude earthquake that struck Myanmar on 28 March, compounding an already dire humanitarian ...
Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period. The S&P 500 dropped nearly 3% for the week, with losses in three of the ...
Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...
The rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was 30% lower among patients receiving nurse-led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results